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Abstract
Since ancient times, natural products (NPs) have been used as anti-infectives, anti-inflam-
matories, antioxidants, analgesics and antitumorals and many compounds derived from 
NPs are in clinical use. The use of plants in traditional medicine for multiple purposes is 
well known, and throughout recent history, metabolites of microbial origin have had an 
extraordinary impact on the welfare of humanity. There is an outstanding diversity of 
chemical structures that nature, and especially microorganisms, are able to produce, due to 
millenniums of evolution. Since only a small amount of the world’s biodiversity has been 
evaluated for potential biological activity, many more useful natural lead compounds await 
discovery, the challenge being how to access this natural chemical diversity. However, the 
validation and selection of primary screening assays, both phenotypic and target-based, 
are vital to guaranteeing a selection of extracts or molecules with relevant pharmacological 
action. The screening of antitumor agents against pancreatic cancer (PC) involves the use 
of established cell lines, cancer stem cells and spheroids that mimic the patient’s tumor. 
Improvements in the discovery of natural products along with the emergence of new tech-
nologies in cancer screening assays, promise the discovery of new and valuable drugs to 
tackle pancreatic cancer in the coming years.
Keywords: natural products, pancreatic cancer, fungi, bacteria, plant, dereplication, 
phenotypic-based screening, target-based screening, high-throughput screening, 
spheroids, organoids
1. Introduction
Pancreatic cancer (PC) is the fourth leading cause of cancer mortality in the United States 
and accounts for about 3% of all newly diagnosed cancers each year. The American Cancer 
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Society estimated that 43,090 people would die from this disease in 2017 [1]. PC is a mul-
tifactorial disease, making it difficult to treat with conventional antitumoral therapy. The 
poor survival rate is likely due to the lack of early diagnosis, rapid disease progression, 
high metastasis rate and unsuccessful outcome of treatment. Although there are different 
types of treatment available for PC, most patients have no recognizable symptoms, making 
early diagnosis difficult [2], and chemotherapies or radiation therapies are often ineffective. 
While surgery is generally considered the best treatment option, only 10–20% of patients 
with PC are surgical candidates. Radiation therapy and chemotherapy are two other com-
mon methods for treating PC. However, the biochemical and physiological characteristics of 
PC appear to limit the effectiveness of these standard forms of therapy, in part due to genetic 
alterations.
Furthermore, recent studies have shown that PC is highly enriched with cancer stem cell 
(CSC) subpopulations that are resistant to current chemotherapeutic drugs and therefore pro-
mote tumor recurrence [3]. CSCs, also called tumor-initiating cells, share many characteris-
tics with normal stem cells, such as asymmetric cell division, where each CSC generates one 
daughter cell with self-renewal capacity and another cell destined to differentiate. The self-
renewal capacity helps to maintain the number of CSCs within the tumor, and its descendent 
progeny generate the mass of the tumor [4]. CSCs also exhibit unique features, such as their 
metastasis ability and the ability to remain in a quiescent state, which protect them from the 
chemotherapeutic drugs developed to target actively dividing cells. Another phenomenon 
frequently seen in PC is the cancer cell epithelial to mesenchymal transition (EMT), associated 
with metastasis, CSC generation and treatment resistance [5].
Although many efforts have been made to find a cure, there is much work left to be done 
because PC is still an unmet medical need affecting an increasing number of patients every year. 
Current research categorizes anticancer agents into two major groups based on their mecha-
nisms of action and origins: cytotoxic anticancer agents and molecular targeted therapeutic 
agents. But the failure of current drugs and treatments can be attributed, in part, to our limited 
understanding of the targets of the disease and to a lack of reliable disease-relevant screen-
ing methods that mimic the key pathophysiological features of cancer. Therefore, efforts now 
should be addressed to developing new models and assay formats, innovative screening tech-
nologies that better summarize in vivo physiology [6], and new, effective and safe compounds 
or combinations.
NPs have been, and still are, one of the main sources of drug discovery. According to the data 
from Newman and Cragg [7], most new FDA-approved drugs between 1981 and 2014 were 
derived from NP structures. Natural constituents are widely distributed in various natural 
sources, including plants, microorganisms and invertebrates. Plant-derived molecules con-
tinue to make up a large portion of the pharmaceuticals in the clinic, and the production of 
antibiotics by microorganisms was one of the biggest breakthroughs in the history of drug 
discovery in the twentieth century. Bacteria and fungi represent two of the most important 
sources for novel therapeutic agents exhibiting the most diverse biological actions. Since 
only a small amount of the world’s biodiversity has been evaluated for potential biological 
activity, many more useful natural lead compounds await discovery, the challenge being how 
to access this natural chemical diversity.
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In the last decades, despite the difficulty of finding novel scaffolds, an increasing number of 
research groups have dedicated numerous efforts to exploring alternative sources, such as 
the marine environment, which has become an extraordinarily rich source of new drugs. At 
present, plants, microorganisms and marine invertebrates are major sources of NPs for dis-
covering novel drugs.
To better understand the huge impact of NPs on cancer pharmaceuticals, it is worth men-
tioning that out of 155 small molecules used as chemotherapeutics, 73 are directly NPs and 
another 40 are derivatives or synthetic NP mimetics [8]. Furthermore, current research trends 
in the field suggest an optimistic future for NPs in cancer prevention and new therapeutics 
drug discovery. Because of the complex chemistry generated by centuries of evolution of NPs, 
more success is expected in drug discovery with NPs than with synthetic molecules. However, 
that complexity of the natural molecules requires a coordinated effort from the interaction of 
multidisciplinary research areas with new and more sophisticated analytical and technical 
expertise in order to extract, isolate, identify and turn them into promising leads.
This chapter provides insights into the advances in cancer drug discovery from NPs using 
high-throughput screening (HTS) technologies, with a special emphasis on the biological 
tools and cell-based assay platforms implemented to untap new NP scaffolds with novelty 
in their mode of actions, and the most promising natural molecules under development 
today.
2. Natural products in drug discovery
The use of plants in traditional medicine is well known for multiple purposes. Over the mil-
lennia, plants have been used as anti-infectives, anti-inflammatories, antioxidants, analge-
sics and antitumorals, and there are many compounds derived from plants used in the clinic. 
The most famous example to date is probably the synthesis of the anti-inflammatory agent 
acetylsalicylic acid (aspirin), derived from salicin and isolated from the bark of the willow 
tree Salix alba L [9]. Other examples are morphine, codeine, digitoxin, quinine and the anti-
tumorals paclitaxel, vincristine and vinblastine, and a long list of other drugs. Metabolites 
of plants still constitute a major area of research but the microbial secondary metabolism of 
bacteria and fungi has been intensely explored in industrial screening programs in the last 
decades.
The biosynthesis and breakdown of proteins, fats, nucleic acids and carbohydrates, which are 
essential to all living organisms, is known as primary metabolism, while the mechanism by which 
an organism biosynthesizes other compounds is known as secondary metabolism. These second-
ary metabolites are known as NPs and are often found to be unique to an organism or species [10]. 
Generally, secondary metabolites are not essential for the growth of an organism and are pro-
duced either as a result of the organism adapting to its surroundings or to act as a possible defense 
mechanism [11]. The biosynthesis of secondary metabolites derived from the fundamental pro-
cesses of photosynthesis, glycolysis and the Krebs cycle which generate limited building blocks, 
but the formation of novel secondary metabolites is infinite. The most important building blocks 
employed in the biosynthesis of secondary metabolites are those derived from the intermediates: 
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acetyl coenzyme A, shikimic acid, mevalonic acid and 1-deoxyxylulose-5-phosphate, which are 
involved in innumerable biosynthetic pathways. The catabolic systems using these secondary 
metabolites are directed by the polyketide synthase (PKS) and the non-ribosomal peptide syn-
thetase (NRPS), which catalyze the elongation of polyketides and synthesis of oligopeptides and 
also the biosynthetic pathways of terpenoids and alkaloids; these systems are really responsible 
for ensuring the diversity of the NPs. The evolution in the biosynthetic pathways may be due to 
natural causes (e.g., viruses, horizontal transfer or environmental changes) or unnatural causes 
(e.g., chemicals or radiation), in an effort by the microorganism to adapt to the environment. 
These modifications and alterations have resulted in a huge library of chemical structures opti-
mized by natural selection that possess a broad array of biological activities. The challenge is how 
to access this chemical diversity and find the appropriate assays to test these biological activities.
In the 2000s, the traditional natural products screening was gradually abandoned because of 
frequent re-discovery of previously isolated compounds, the inherent technical difficulties 
associated to the isolation of active constituents of extracts, the incompatibility of NP extracts 
with HTS campaigns, and the structural complexity and low titer production of NPs, which 
required total synthesis and derivatization, sometimes economically and synthetically chal-
lenging. NP discovery was therefore replaced by molecular target-based drug discovery using 
large synthetic combinatorial libraries. However, the success of these combinatorial libraries 
in cancer have been brought into question since only one compound from this origin has been 
approved by the FDA, in 2005, for treatment of renal cell carcinoma, and in 2013, for treating 
thyroid cancer. This antitumor compound is sorafenib, co-developed and co-marketed by Bayer 
and Onyx Pharmaceuticals. Combinatorial libraries lack the structural diversity and complex-
ity given by nature to NPs. In a further step, the diversity-oriented synthesis (DOS) approach 
was developed to mimic NPs and the resulting compounds are currently being tested in a large 
number and variety of biological screens in order to determine their role as a promising hit [12].
Nonetheless, recent advances in technology and sensitive instrumentation for the rapid iden-
tification of novel bioactive NPs and structure elucidation have opened up a new era and 
greatly improved the NP discovery process [13]. NPs, their semi-synthetic derivatives and 
natural product-inspired compounds still represent one of the most important sources of 
chemical diversity and bioactive novel structures ever described [8, 14].
The extremely prolific production of novel molecules by some groups of microorganisms, 
especially some taxa of actinomycetes (a phylum of Gram-positive bacteria) and fungi, did 
not require the use of an unlimited number of cultivation conditions to ensure that novel 
molecules were produced. In fact, for decades researchers have agreed on the application of 
a maximum of three to four production media at a time are sufficient to exploit the produc-
tion of new bioactive molecules [15]. Microbial extracts have been largely exploited in anti-
biotic discovery, but new applications of these secondary metabolites are emerging, such as 
their relevant activity as antitumor agents. In recent years, increasing numbers of complete 
annotated genomes have been confirming the presence of a huge biosynthetic potential in 
bacteria and fungi, in many cases only detected as cryptic pathways from genome mining of 
biosynthetic pathways [16]. We still do not know the most important factors conditioning the 
nutritional requirements and secondary metabolism regulatory factors of most of the species 
screened which might be producing molecules quite below the detection threshold. Further 
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studies are in progress to modulate and heterologously express the secondary metabolism of 
microorganisms, opens up an emerging vast field of research in synthetic biology.
Furthermore, the difficulty of discovering novel molecules and the recurrent re-discovery 
problem of old, well-known molecules has required in parallel moving away from tradi-
tional approaches challenging the secondary metabolism of these species from quite different 
culture-based perspectives. The challenge of finding new molecule classes from libraries of 
secondary metabolites produced by microorganisms has required a change of paradigm with 
a shift in the number of new extracts tested and an improvement in the strain selection condi-
tions and the nutritional conditions required for the production of novel molecules.
Access to the microbial diversity in the environment has traditionally been focused not only 
on intensive sampling from widely diverse geographical locations and habitats, but also other 
novel approaches were introduced in the 2000s. One of these approaches for drug discovery 
from microbial strains involves the application of the One Strain Many Compounds (OSMAC) 
method, which attempts to induce silent biosynthetic clusters leading to the accumulation 
of compounds by a combination of cultivation and nutritional conditions. OSMAC helps to 
determine the modulating effect that altered culture conditions (i.e., media composition, tem-
perature, osmolarity and pH) may have on the secondary metabolite production of microor-
ganisms [17]. Examples of such culture variations include the use of different liquid or solid 
media, such as solid beans or rice medium or the mimicry of extreme habitats by cultivating 
at colder temperatures or using highly saline media [18]. The OSMAC approach has been rou-
tinely used at Fundación MEDINA, a reference center for natural products drug discovery, 
to exploit our microbial strain collection of 190,000 strains (in part inherited from the Merck 
& Co. Inc. and Cubist Collections) to generate a NP Library of more than 180,000 extracts. 
MEDINA has introduced small-scale bacterial and fungal fermentations in tubes and deep 
well microplates that can be readily adapted to automated liquid handling equipment for fur-
ther extraction and processing. Thus, the reduction of the fermentation volumes opens up the 
possibility of testing multiple nutritional conditions while offering the possibility of exploring 
minor groups of isolates and understanding their requirements up to as many as 20 different 
media. An average of the best eight fermentation media covering the largest metabolic space 
of the producing strains was shown to ensure an increase in the numbers and diversity of the 
strains tested [19]. All crude extracts are obtained from these cultures, using organic solvents 
to collect most of the secondary metabolites generated both, inside the microbial cells and 
excreted to the culture media. In the case of extracts from plants or invertebrates, different 
parts of the plant or animal are crushed and then extracted, also with organic solvents.
Screening of NPs, just as synthetic compounds, is performed following different approaches 
depending on the paradigm chosen for each application. In the case of antitumor screening, 
both target- and phenotypic-based assays are normally used. The screening methods are dis-
cussed below in Section 2.1 of this chapter, and the process of identifying the new molecules 
is summarized in Figure 1.
Once the active extracts in screening are detected, chemical identification of the novel com-
pounds is necessary. Although diverse strategies are followed for isolating the active com-
pounds from microorganisms, here we describe one of the most exhaustive approaches 
(Figure 1). The process of identifying known compounds responsible for the activity of an 
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extract prior to bioactivity-guided isolation is referred to as dereplication, and must be done 
as soon as possible in drug discovery process [20]. An early dereplication of known molecules 
may be performed through different systematic analysis techniques. One of the most suc-
cessful methods combines liquid chromatography with high resolution mass spectrometry 
(LC-HRMS). Identification of known NPs with no chemical or pharmacological interest is 
inevitable and should be detected early through the comparison of analytical data against 
proprietary LC-MS libraries of microbial metabolites in research groups with long experience, 
or against public and commercial libraries of NPs, such as Chemspider or the Chapman & 
Hall Dictionary of NPs.
Active extracts containing novel components are of great interest and the molecular identifica-
tion and isolation of these novel compounds are required. To do this, first, the microbial strain 
is regrown in the same conditions on a medium scale (150 mL), and bioassay-guided extract 
fractionation is carried out. Enriched fractions are generated through semipreparative HPLC 
method using proper separation columns and solvent gradient. The fractions are then tested 
for activity following the screening paradigm. In some cases, LC/HRMS and NMR derepli-
cation allow identify the bioactive components at this stage, but in most cases, regrowth on 
Figure 1. Schematic representation of the high-throughput screening and integrated dereplicating chemistry platform 
used to discover molecules from microbial extracts.
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a large scale (1–3 L) is needed to have enough quantity of the bioactive compounds, whose 
structure elucidation is eventually performed using LC-HRMS and nuclear magnetic reso-
nance (NMR) [21]. In the case of NPs from plants or invertebrates, similar bioassay-guided 
fractionation, dereplication, elucidation and chromatographic purification steps are followed 
[22, 23].
Undoubtedly, the discovery of drugs from natural products requires a multidisciplinary 
team: a group of experienced microbiologists or biologists working on plants or invertebrates 
to generate a collection of samples with the greatest possible biodiversity, researchers with 
experience in screening and with skills to work with HTS and robotic equipment, and lastly, a 
group of chemists with extensive knowledge about the chemistry of natural products.
2.1. Screening in pancreatic cancer
Screening has played a critical role in the discovery of leads that are further optimized for 
their properties, eventually leading to clinical candidates and drugs. The tremendous prog-
ress made in life sciences has resulted in the definition of many pathological processes and 
mechanisms of drug action. Drug discovery for cancer is carried out using both, target-based 
and phenotypic-based approaches. Target-based approaches to drug discovery are exten-
sively used in the pharmaceutical industry but there are very few fully validated drug targets 
in cancers that are dependent on the tumor microenvironment, such as pancreatic cancer [24]. 
Due to this lack of avowed target in PC and the advances in cell culture, the most widely used 
approaches are phenotypic.
The latest advancements have led to the establishment of various molecular and cellular bio-
assays in conjunction with HTS methods. HTS decreases the amount of testing compound 
required so that only microgram quantities are needed. This is advantageous for certain NPs 
that are difficult to isolate and purify, and permits assaying compounds that are difficult 
to synthesize. Fluorescent methods are probably the classic choice for HTS, as they allow 
the best discrimination of the signal of interest from the background, though luminescent 
methods or other new technologies like AlphaScreen™, fluorescence resonance energy trans-
fer (FRET) technology, time-resolved fluorescence (TRF) and fluorescence polarization are 
becoming more relevant. The current move is away from the traditional 96-well plate to 384- 
or 1536-well plates, where reagent costs are typically 100 times lower, and assay volumes 
decrease from 200 to 5–10 μl, and the quantity of compound or crude extract assayed drops 
to nanoliters. The use of such a low volume in assays leads to the need for liquid handling 
equipment, robotic platforms and new technology advancements such as Acoustic Droplet 
Ejection Technology [25].
Furthermore, image acquisition using robotic fluorescent microscopy and automated image 
analysis, generally referred to as high-content screening (HCS), has become an essential tool 
in early drug discovery programs, especially in cancer research. High-content cellular imag-
ing is increasingly meeting the challenges of high-throughput needs and facilitating the inte-
gration of disease-relevant screens in cancer models such as three-dimensional (3D) cultures. 
NP screening has been adapted to HTS technologies, and a huge effort has been made to 
adapt the classical NP research laboratories to centralized HTS facilities.
Drug Discovery from Natural Products for Pancreatic Cancer
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The increase of chemodiversity, together with HTS methods and novel assay models in can-
cer research, make the use of NPs a promising source of anticancer drugs. The two main 
approaches to drug discovery for PC, target- and phenotypic-based screening, are described.
2.1.1. Target-based screening in pancreatic cancer
A target for a disorder is only fully validated when there is a registered drug for which it can 
be shown that the principle mode of action is by modulation of the target. For decades, PC was 
commonly treated with 5-fluorouracil (5-FU), also used in other types of cancer. The suicide 
inhibitor 5-FU works through irreversible inhibition of thymidylate synthase [26]. The cyti-
dine analog Gemcitabine (2′,2′-difluoro 2′-deoxycytidine), which replaced 5-FU, was approved 
by the Food and Drug Administration (FDA) in 1996 [27], becoming the standard first-line 
treatment for PC. In 2005, the FDA approved the combination of gemcitabine and erlotinib 
[28]. Erlotinib is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth fac-
tor receptor (EGFR). Other combination clinical trials have been conducted since then.
A combination of oxaliplatin, irinotecan, 5-FU and leucovorin, called FOLFIRINOX [29], is 
chemotherapy regimen confined to patients with good performance status because of its high 
toxicity and severe side effects. Oxaliplatin is a platinum-based antineoplastic agent, irinote-
can prevents DNA from unwinding by inhibition of topoisomerase 1 and leucovorin (5-for-
myltetrahydrofolate) is an adjuvant in cancer chemotherapy.
Nab-paclitaxel, a nanoparticle albumin-bound paclitaxel, which is natural product from 
extract of Taxus brevifolia (Pacific yew) [30], targets tubulin and destroys cancer cells by pre-
venting the normal breakdown of microtubules during cell division. In September 2013, the 
FDA-approved nab-paclitaxel for use in treating advanced PC. The last therapy approved 
for PC, in 2015, was the combination of Onivyde (irinotecan liposome injection), 5-FU and 
leucovorin. Despite great efforts, many years of research and numerous studies, these chemo-
therapeutic options for treating PC are far from satisfactory at present [31].
In recent years, further attempts have been made to discover new chemotherapeutics directed 
to new targets which may provide an approach for PC prevention and treatment. Pathways 
with relevant novel targets are: K-ras (Raf [32], MAPK, Erk, PI3Ks, PDK-1 [33]; p53 [34]; growth 
factor (EGF, EGFR [35], FGF, FGFR [36], VEGF [37], IGF [38]) and the pathway of epithelial to 
mesenchymal transition (Wnt/β-catenin [39], TNFα [40], Notch [41], Snail-1, Slug, E-cadherin 
[42]). Clinical trials have been developed to evaluate some of these targets but the results have 
been disappointing. Studies testing the antibody bevacizumab, which blocks angiogenesis by 
inhibiting vascular endothelial growth factor A (VEGF-A) [43] and cetuximab, which blocks 
ligand-binding domain of EGFR [44], have been negative.
Although these experimental targets are widely used for target-based screening in PC, there 
is an urgent need to identify innovative therapeutic targets. Current approaches to the dis-
covery of new biomarkers and targets range from the use of microarrays for gene expression 
profile of PC patients versus healthy controls [45], to proteomic [46] or secretome profiles [47].
Few examples of NPs have been reported for PC with different target-directed mechanisms. 
Some of the more representative ones are described below and summarized in Table 1.
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The most advanced, which has been approved by FDA, is nab-paclitaxel, derived from natu-
ral paclitaxel [48], mentioned above in the chapter. Another example, reported by He et al. 
[49] is hispidulin, a flavone found in some plants including artemisia and salvia, which tar-
gets the VEGF receptor 2-mediated PI3K/Akt/mTOR signaling pathway in endothelial cells, 
leading to the suppression of pancreatic tumor growth and angiogenesis.
Other class of secondary metabolites of plants with effectiveness in PC is terpenoids. The 
mechanism of the terpene antitumor effects is the inhibition of posttranslational isopre-
nylation of proteins regulating cell growth [50]. For instance, betulinic acid, a triterpenoid 
obtained from the bark of Betula pubescens, exhibits potent antitumor activities and can down-
regulate lamin B1; knockdown of lamin B1 significantly attenuates the proliferation, invasion 
and tumorigenicity of PC cells [51]. Moreover, the epothilone B lactam ixabepilone, a micro-
tubule stabilizer produced by a Gram-negative bacterium Sorangium cellulosum, which was 
approved by the FDA for breast cancer treatment in 2007, was assayed for PC in a Phase II trial 
in patients with advanced pancreas cancer [52], showing encouraging activity in the patients.
Additionally, the arachidonic acid (AA) pathway plays a key role in carcinogenesis. The 
AA pathway metabolic enzymes phospholipase A2s (PLA2s), cyclooxygenases (COXs) and 
lipoxygenases (LOXs), and their metabolic products, such as prostaglandins and leukotrienes, 
have been considered novel preventive and therapeutic targets in cancer [53]. AA pathway 
inhibitory NPs have been developed as chemopreventive and therapeutic agents against sev-
eral cancers. For example, apigenin, a flavonoid widely found in plants, suppresses inducible 
COX-2 expression and inhibits the growth of PC cells in vitro and in vivo by IKK-β-mediated 
NF-κB activation [54]. Epidemiologic studies suggested that apigenin is related to a decreased 
risk of certain cancers, including PC [55]. Another is baicalein (5,6,7-trihydroxyflavone), found 
NP compound or derivate Ref. Source Target




Taxus brevifolia (tree) Tubulin (microtubules)
Hispidulin [49] Artemisia and salvia (plants) VEGF receptor 2-mediated PI3K/Akt/
mTOR signaling pathway
Betulinic acid [51] Betula pubescens (tree) Lamin B1





Widely distributed in plants COX-2, IKK-β-mediated NF-κB activation
Baicalein [56] Scutellaria baicalensis and S. 
lateriflora (plant)
Lipoxygenases (LOXs)
Ellagic acid [57] Fruits, nuts and vegetables Arachidonic acid (AA) pathway
[6]-Gingerol [58] Zingiber officinale (plant) Arachidonic acid (AA) pathway
Thymoquinone [59] Nigella sativa (plant) Arachidonic acid (AA) pathway
Triptolide [60] Tripterygium wilfordii (plant) Arachidonic acid (AA) pathway
Table 1. Summary of experimental NPs and derivatives for PC treatment with known target.
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in the roots of Scutellaria baicalensis and S lateriflora, which inhibits LOXs and in turn down-
regulates Bcl-2, increases Bax, increases cytosolic cytochrome c, and activates caspase-9, 
promoting apoptosis and exhibiting anticancer activity against PC cells [56]. Ellagic acid, a 
hydrolyzed metabolite of ellagitannin found in certain fruits, nuts and vegetables, has been 
reported to possess anti-pancreatic cancer properties, targeting AA pathway. Zhao et al. [57] 
described that ellagic acid inhibited PC growth in PANC-1 xenografted mice, by suppressing 
various pro-tumorigenic mediators. Other natural compounds with described activity for this 
pathway are [6]-gingerol, a phenol constituent of the plant Zingiber officinale Roscoe (ginger) 
[58]; thymoquinone [59], derived from black cumin Nigella sativa and triptolide [60], a diter-
penoid isolated from Tripterygium wilfordii. Many more NPs that modulate AA pathway are 
under research for other cancer types and could also be active against PC.
2.1.2. Phenotypic-target screening in pancreatic cancer
While all of the early drugs were discovered by phenotypic screening, the past three decades 
have given rise to new technologies for performing HTS that have since dominated the phar-
maceutical industry. Development of patient-derived cell cultures, three-dimensional (3D) 
culture, organotypic systems, advances in cell imaging, microfluidics and nanotechnologies 
are the future trends in drug discovery and development.
Patient-derived cell cultures offer a more clinically relevant model for testing novel gene and 
cell-based therapies. These models are decidedly valuable in cancer research, where highly 
selective drugs targeted at genetically defined clinical subtypes are needed to support a more 
patient-centric approach to drug development [61]. Potential drugs have been tested against 
patient-derived primary cancer subtypes for various cancers, with promising results in glio-
blastoma [62] and leukemia [63]. The problem in PC research is that there are few in vitro 
models of exocrine pancreas development and primary human pancreatic adenocarcinoma 
(PDAC), and the models are just starting to be established. The use of surgically resected pan-
creatic cancer tissue is difficult because of the limited amount of residual pancreatic cancer 
tissues remaining after the large amount of cancer tissue has been used in the histopathologic 
examination for diagnosis. To overcome this limitation, researchers have tried to establish 
cancer cell lines from patient-derived cancer tissues, but this approach has not been very suc-
cessful due to specific histopathologic characteristics of PC, such as low cancer cellularity and 
the extensive desmoplastic reactions by the associated fibroblasts. Consequently, the number 
of established patient-derived PC cell lines is currently much lower than that of other cancers 
[64–66], there currently being only 11 cell lines from the American Type Culture Collection 
and another 4 from the European Collection of Authenticated Cell Cultures (ECACC). These 
are widely used despite the limitations, such as the in vitro cell culture conditions which mod-
ify cells over time, losing the expression of markers or enriching specific cell populations. 
Patient-derived tumor xenograft mice models (PDXs) have been used recently for predicting 
patient responses for patient-selection strategies [67], but this animal model cannot be used 
for massive drug discovery for obvious reasons.
Recent evidence suggests the existence of small populations of CSC, which are believed to be 
responsible for tumor initiation and progression as well as resistance to chemotherapy and 
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radiation. Identification of the regulatory mechanisms and signaling pathways involved in 
CSC are expected to help researchers identify and design novel agents that target this resis-
tant cell population in PC. Pancreatic CSC can be allowed to divide and grow in ultra-low 
binding tissue culture dishes to form multicellular spheroids that will favor the formation of 
multicellular tissues with the appropriate cell-cell and cell-matrix (ECM) interactions neces-
sary for full functionality. Natural and synthetic biomaterials and nanomaterials are used 
to build these 3D cultures, providing a robust architecture in 96- and 384-well formats. This 
technology is being successfully applied in cancer models [68], although the culture medium 
and materials used still need to be improved.
Coupled with 3D cultures, HCS imaging systems have been developed, with huge advances in 
microscopy and image-informatics solutions [69]. Image acquisition using robotic fluorescent 
microscopy and automated image analysis has become an essential tool in early drug discov-
ery programs. HCS cellular imaging has increasingly met the challenges of high-throughput 
needs and facilitates the integration of disease-relevant models and screens at early stages of 
the drug discovery process [70]. Although various PC cell lines can grow as spheroids in 3D 
cultures, it is unclear how well they reflect the properties of the original human tumor [71, 72].
There are some examples of promising NPs against pancreatic cancer obtained and described 
through phenotypic-based screening and nutritional studies, which have been reported in 
scientific publications and patents and are summarized in Table 2.
One of the main currents for treating cancer using natural plants is traditional Chinese medi-
cine. Chinese medicine is an old form of medicine built on a foundation of more than 2500 years 
of Chinese medical practice. In recent times, new studies have been made and new patents 
have been registered in relation to this ancient science with the aim of modernizing traditional 
Chinese medicine [73]. Some patents of PC treatment have been registered on a combination of 
tens of herbal and other NPs, based on a secret prescription handed down from ancestors and 
on traditional Chinese medical theory [74, 75]. These patents report a very high efficacy in clini-
cal studies and have shown a total recovery of up to 90% in 2–5 years. This percentage is incred-
ibly high so a confirmation in other populations would be necessary to validate the results, but 
there is no record of the patents being tested in other countries. Additionally, the principal com-
ponents of the flower Paeonia lactiflora, albiflorin and paeoniflorin, which are a functional food 
ingredient widely used for more than 2000 years in traditional Chinese medicine, have been pat-
ented for pancreatic cancer prevention and treatment [76]. In vitro and in vivo experiments show 
that albiflorin has antitumoral activity and may provide a new option for the clinical treatment 
of tumors, although these trials are only in the first stage of drug development.
Furthermore, dietary proanthocyanidins mostly present in apples, pears and pulses, has been 
suggested to reduce the risk of pancreatic cancer by 25% [77]. Another example is Chelidonium 
majus L. (Papaveraceae), a medicinal herb with antitumoral activity that is widely found in 
Europe. High cytotoxic activity against pancreatic cancer has been reported by an extract of 
C. majus [78]. Also, Sarcaboside B was isolated from the whole plant of Sarcandra glabra and 
shows in vitro results of antineoplastic activity in PC cells according to a patent posted by 
Ding Shengyu [79]. Usnic acid is extracted from lichen and has been used for its antimicrobial 
activities. Its effect against cancer cells was first reported over 30 years ago, and specifically its 
effect has been observed in PC cells [80].
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Marine samples, from marine microorganisms, algae or invertebrates, are increasingly more 
relevant as sources for cancer chemoprotectives. The lead compound, Ecteinascidin-743 
(Yondelis®), is the first marine anticancer agent approved in the European Union for patients 
with Soft Tissue Sarcoma (STS) and for the treatment of Relapsed Ovarian Cancer. In the case 
of PC, marine samples still have a long way to go before they can be used in treatment but there 
is a whole universe of compounds waiting to be discovered. One example is Spirulina platensis, 
which is a blue-green alga used as a dietary supplement because of its hypocholesterolemic 
properties. Among other bioactive substances, it is also rich in tetrapyrrolic compounds closely 
related to bilirubin molecule, a potent anti-proliferative agent. The anti-proliferative effects 
of S. platensis were observed against PC cells and were also shown in vivo where inhibition 
of PC growth was evidenced from the third day of treatment in a mice model [81]. Another 
compound of marine origin, Aplidine (Dehydrodidemnin B), extracted from the invertebrate 
ascidian Aplidium albicans, shows dose-dependent cytotoxic activity against PC cells as well as 
significant activity against mice bearing human cancer xenografts. Aplidine’s mechanisms of 
action seem to be mediated by the AKT pathway and the reduction in ERK activation [82]. Also, 
Manzamenone O was isolated from a marine sponge and has been patented against PC [83].
From the fungi kingdom, polysaccharide-K (PSK, krestin) is one of the most commonly used 
medicinal mushroom extracts, with a long history in cancer therapy in Asia, especially in 
Japan [84]. Zhang et al. [85] have reported that PSK decreases the invasiveness of a human PC 
cell line. Also, antroquinonol, a ubiquinone derivative isolated from the mushroom Antrodia 
camphorata, induced a concentration-dependent inhibition of cell proliferation in PC [86].
NP compound or derivate Ref. Source Approach
Albiflorin and paeoniflorin [76] Paeonia lactiflora (flower) In vitro and in vivo
Proanthocyanidins [77] Apples, pears and pulses (fruit) Epidemiological study
Extract from Chelidonium majus L. [78] Chelidonium majus L. (plant) In vitro and in vivo
Sarcaboside B [79] Sarcandra glabra (plant) In vitro
Usnic acid [80] Lichen In vitro
Extract from Spirulina platensis [81] Spirulina platensis (blue-green alga) In vitro and in vivo
Aplidine [82] Aplidium albicans (ascidian, 
invertebrate marine)
In vitro and in vivo
Manzamenone O [83] Plakortis sp. (marine sponge) In vitro
Polysaccharide-K [84, 85] Trametes versicolor (mushroom) In vitro
Antroquinonol [86] Antrodia camphorate (mushroom) In vitro
MMH01 [87] Antrodia cinnamomea (fungi) In vitro
Beauvericin [88] Fusarium oxysporum (fungi) In vitro
Globosumones [89] Chaetomium globosum (fungi) In vitro
MDN-0090 [90] Onychola sp. (fungi) In vitro
Table 2. Summary of experimental NPs and derivatives for PC treatment from phenotypic-based screening and 
epidemiological studies.
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Among the microbial NPs, very few are described in bibliographies. One of those published 
is the compound MMH01, which is isolated from the parasitic fungus Antrodia cinnamomea 
on aromatic tree Cinnamomum kaneirai Hay. (Lauraceae), which markedly inhibited growth of 
a PC cell line [87]. Other examples are the compound beauvericin, extracted from the fungal 
strain Fusarium oxysporum, which inhibits migration of the metastatic PC cell [88], and glo-
bosumones, from the Sonoran Desert endophytic fungus Chaetomium globosum, with inhibi-
tory activity of cell proliferation in PC cells [89]. Also noteworthy is MDN-0090, a compound 
patented by our research group at Fundacion MEDINA, from a fungus identified as Onychola 
sp. [90], with in vitro activity against PC. This compound was obtained through a phenotypic-
based screening of more than 90,000 microbial extracts from Medina’s NP Library following 
a cytotoxicity screening in 2D cancer cell culture and a dereplication and identification of the 
novel compound. Promising results with this novel compound have been obtained from an in 
vivo mice model of disease (unpublished data).
2.2. Future trends in screening in pancreatic cancer
Although many efforts have been made to improve the technology, research models and 
sources for finding a cure, there is much work left to be done in pancreatic cancer research. 
Here, we summarize the future trends in this research.
One solution that more closely mimics tumor properties is the use of an alternative 3D model 
for tissues, termed organoids, which go one step further. 3D organotypic models have poten-
tial for bridging the gap between cell-based discovery and complex animal models. Adult 
stem cells are prepared from human adult tissues and embedded in a three-dimensional 
matrix, where they self-organize into epithelial structures that resemble the original organ. 
One example for PC was developed by Huang et al. [91], who differentiated human plu-
ripotent stem cells (PSCs) into exocrine progenitor organoids that formed ductal and acinar 
structures in culture, expressing the mutations frequently found in patients. These organ-
oids would recapitulate the properties of the original tumor, maintaining the differentiation 
status, histoarchitecture, phenotypic heterogeneity and retaining patient-specific physiologic 
changes. The publication of Boj et al. [92] describes the obtaining of PC tissues from patients 
undergoing surgical resection. The tissue is minced, digested with enzymes, embedded in 
matrigel and culture with propagation until 20 passages (~6 months) or is cryopreserved, 
which makes it a very useful model. Related to this is the new creation of living organoid bio-
banks [93], which consist of a collection of cryopreserved organoids from patients. The abil-
ity to create organoids from individual tumors and the enormous clinical diversity of these 
specimens can be extremely useful for drug discovery. One large collection of these cultures 
is the Hubrecht Organoid Technology (HUB) “living” biobank [94]. The HUB is part of the 
Human Cancer Models Initiative in collaboration with The National Cancer Institute, Cancer 
Research UK, and the Wellcome Trust Sanger Institute. This “living” biobank stores approxi-
mately 1000 cancer cell models that best represents the hallmarks and diversity of human 
breast, colorectal, lung, pancreatic and prostate cancer. The organoids generated have been 
assayed to analyze drug sensitivity to a vast array of anticancer drugs. This well-characterized 
library of cultures, with genome sequenced and clinical data from patients, has been created 
to aid in basic research and explore novel therapeutic strategies and drugs, being accessible 
to industry and academia [95].
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Therefore, tumor organoids can be used in PC models and for drug screening to identify preci-
sion therapy strategies, but nowadays only a few laboratories have enough equipment, facili-
ties and access to patient samples to develop them. One step further is the organ-on-a-chip, 
still under development. This technology is essentially miniaturized microfluidic perfusion 
systems which allow long-term in vitro growth of primary cells and tissues in a format that is 
viable for scaling up for high-throughput discovery campaigns. These systems model the com-
plex tissue microenvironment and communication, reproducing in vivo tissue and organ func-
tionality. One example reported by Maschmeyer et al. is a four-organ-chip system that mimics 
human liver, skin, intestine and kidney [96]. Furthermore, the use of microfluidic perfusion 
chambers in these systems permits the homeostatic function of the organ as if it were the blood 
flow, supplying nutrients and discharging catabolic metabolites [97]. We look forward to see-
ing how these promising advances develop in the new era of drug discovery in PC research.
3. Conclusion
In this scenario, PC is still an unmet medical need and new therapies need to be discovered. The 
ancestral use of natural products in medicine continues in force, but with novel approaches. 
The increase of chemodiversity together with HTS methods and novel assay models in cancer 
research make the use of NPs a promising source of novel anticancer drugs. Many more use-
ful natural lead compounds await discovery and the challenge is how to access this natural 
chemical diversity. More and more multidisciplinary teams are needed to access the world’s 
biodiversity, identify novel compounds and evaluate their potential biological activity.
Promising compounds are currently being tested and many more are expected to be found 
from diverse natural product sources, with the help of the new trends in cancer research.
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